Aquestive Therapeutics
AQST67
$4.99arrow_drop_up3.09%$0.15
Penny Stock
AQST67
$4.99
arrow_drop_up3.09%Performance History
| Key Stats | |
|---|---|
| Open | $4.82 |
| Prev. Close | $4.84 |
| EPS | -0.36 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $440.72M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 4.75 | 4.92 |
| 52 Week Range | 1.25 | 6.23 |
| Ratios | |
|---|---|
| EPS | -0.36 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Aquestive Therapeutics (AQST)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Mr. Daniel Barber
- Headquarters
- Warren
- Employees
- 130
- Exchange
- NASDAQ
Keep an eye on Aquestive Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Aquestive Therapeutics 's (AQST) price per share?
The current price per share for Aquestive Therapeutics (AQST) is $4.99. The stock has seen a price change of $0.15 recently, indicating a 3.1% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Aquestive Therapeutics (AQST)?
For Aquestive Therapeutics (AQST), the 52-week high is $6.23, which is 24.85% from the current price. The 52-week low is $1.25, the current price is 298.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Aquestive Therapeutics (AQST) a growth stock?
Aquestive Therapeutics (AQST) has shown an average price growth of 0.41% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aquestive Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Aquestive Therapeutics (AQST) stock price performance year to date (YTD)?
As of the latest data, Aquestive Therapeutics (AQST) has a year-to-date price change of 148.26%. Over the past month, the stock has experienced a price change of 21.12%. Over the last three months, the change has been 82.78%. Over the past six months, the figure is -18.06%. Looking at a longer horizon, the five-year price change stands at 40.96%.
help
Is Aquestive Therapeutics (AQST) a profitable company?
Aquestive Therapeutics (AQST) has a net income of -$7.87M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 59.25% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0.27% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $50.58M, with a revenue growth rate of 6.09%, providing insight into the company's sales performance and growth. The gross profit is $29.97M. Operating income is noted at -$14.89M. Furthermore, the EBITDA is $2.56M.
help
What is the market capitalization of Aquestive Therapeutics (AQST)?
Aquestive Therapeutics (AQST) has a market capitalization of $440.73M. The average daily trading volume is 1.03M, indicating the stock's liquidity and investor engagement.
News
CALENDAR OF EVENTS
6/27/2024Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
DIRECTORS AND OFFICERS
6/3/2024Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
5/24/2024
5 Small Drug Stocks to Buy From a Recovering Industry
CALENDAR OF EVENTS
5/9/2024Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
5/7/2024
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
5/7/2024
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates